T-Cell-Derived miRNA-214 Mediates Perivascular Fibrosis in Hypertension.


Journal

Circulation research
ISSN: 1524-4571
Titre abrégé: Circ Res
Pays: United States
ID NLM: 0047103

Informations de publication

Date de publication:
10 04 2020
Historique:
pubmed: 18 2 2020
medline: 5 11 2020
entrez: 18 2 2020
Statut: ppublish

Résumé

Despite increasing understanding of the prognostic importance of vascular stiffening linked to perivascular fibrosis in hypertension, the molecular and cellular regulation of this process is poorly understood. To study the functional role of microRNA-214 (miR-214) in the induction of perivascular fibrosis and endothelial dysfunction driving vascular stiffening. Out of 381 miRs screened in the perivascular tissues in response to Ang II (angiotensin II)-mediated hypertension, miR-214 showed the highest induction (8-fold, T-cell-derived miR-214 controls pathological perivascular fibrosis in hypertension mediated by T cell recruitment and local profibrotic cytokine release.

Identifiants

pubmed: 32065054
doi: 10.1161/CIRCRESAHA.119.315428
pmc: PMC7147427
doi:

Substances chimiques

MicroRNAs 0
Mirn214 microRNA, mouse 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

988-1003

Subventions

Organisme : British Heart Foundation
ID : FS/14/49/30838
Pays : United Kingdom
Organisme : British Heart Foundation
ID : RG/14/3/30706
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/S005412/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R015651/1
Pays : United Kingdom
Organisme : British Heart Foundation
ID : CH/11/2/28733
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn

Références

Am J Physiol Renal Physiol. 2017 Aug 1;313(2):F163-F173
pubmed: 28404591
Nucleic Acids Res. 2019 Jul 2;47(W1):W199-W205
pubmed: 31114916
Circ Res. 2017 May 12;120(10):1584-1597
pubmed: 28298295
J Am Soc Nephrol. 2014 Jan;25(1):65-80
pubmed: 24158985
Cardiovasc Res. 2019 Feb 1;115(2):357-372
pubmed: 30239604
Hypertension. 2009 Jul;54(1):3-10
pubmed: 19487587
Hypertension. 2017 Oct;70(4):660-667
pubmed: 28784646
Am J Physiol Heart Circ Physiol. 2015 Sep;309(5):H906-17
pubmed: 26071547
Cardiovasc Res. 2018 Sep 1;114(11):1547-1563
pubmed: 29800237
Biochim Biophys Acta. 2013 Jul;1832(7):1049-60
pubmed: 23046809
Cardiovasc Res. 2018 Mar 15;114(4):529-539
pubmed: 29394331
Hypertension. 2015 Nov;66(5):1023-33
pubmed: 26351030
FASEB J. 2016 May;30(5):1987-99
pubmed: 26873938
Eur Heart J. 2019 Nov 1;40(42):3459-3470
pubmed: 31504461
Oxid Med Cell Longev. 2019 Jul 18;2019:6721531
pubmed: 31396305
J Physiol. 2003 Oct 1;552(Pt 1):185-95
pubmed: 12844513
Circulation. 2014 May 27;129(21):2111-24
pubmed: 24657994
Pulm Circ. 2016 Mar;6(1):109-17
pubmed: 27162619
Br J Pharmacol. 2017 Oct;174(20):3496-3513
pubmed: 28063251
Hypertension. 2010 Jul;56(1):36-43
pubmed: 20530296
J Am Soc Nephrol. 2018 Oct;29(10):2518-2528
pubmed: 30049682
Cardiovasc Res. 2020 Mar 1;116(3):721-735
pubmed: 31250885
Cardiovasc Res. 2018 Nov 1;114(13):1806-1815
pubmed: 29931051
Circulation. 2011 Sep 20;124(12):1370-81
pubmed: 21875910
J Clin Invest. 2012 Apr;122(4):1222-32
pubmed: 22426211
Circ Res. 2018 Aug 31;123(6):638-640
pubmed: 30355241
Genome Biol. 2014;15(12):550
pubmed: 25516281
Immunogenetics. 2016 Jan;68(1):43-54
pubmed: 26563334
Immunity. 2019 Feb 19;50(2):378-389.e5
pubmed: 30784579
Cell Res. 2014 Oct;24(10):1164-80
pubmed: 25223704
J Clin Invest. 2016 Apr 1;126(4):1607
pubmed: 27035819
Lancet. 2016 Oct 8;388(10053):1659-1724
pubmed: 27733284
Circ Res. 2015 Mar 13;116(6):1022-33
pubmed: 25767287
Cardiovasc Res. 2018 Mar 1;114(3):368-377
pubmed: 29309533
Cardiovasc Res. 2018 Feb 1;114(2):312-323
pubmed: 29036612
EMBO J. 2017 Aug 15;36(16):2373-2389
pubmed: 28694244
Hypertension. 2020 Feb;75(2):383-392
pubmed: 31838904
Sci Rep. 2017 Mar 09;7:44131
pubmed: 28276483
Cardiovasc Res. 2018 Oct 1;114(12):1569-1570
pubmed: 30247682
Arterioscler Thromb Vasc Biol. 2013 Jun;33(6):1313-9
pubmed: 23520167
Curr Hypertens Rev. 2017;13(1):8-15
pubmed: 28412914
Eur Heart J. 2006 Nov;27(21):2588-605
pubmed: 17000623
Circ Res. 2014 Feb 14;114(4):616-25
pubmed: 24347665

Auteurs

Ryszard Nosalski (R)

From the Institute of Cardiovascular and Medical Sciences, University of Glasgow, United Kingdom (R.N., E.M., A.N.D.C., D.S., P.M., D.G., T.J.G.).
Department of Medicine, Jagiellonian University Medical College, Krakow, Poland (R.N., M.S., M.N., D.S., G.W., G.O., T.J.G.).

Mateusz Siedlinski (M)

Department of Medicine, Jagiellonian University Medical College, Krakow, Poland (R.N., M.S., M.N., D.S., G.W., G.O., T.J.G.).

Laura Denby (L)

Centre for Cardiovascular Science, Queen's Medical Research Institute, University of Edinburgh, United Kingdom (L.D., J.R., A.H.B.).

Eilidh McGinnigle (E)

From the Institute of Cardiovascular and Medical Sciences, University of Glasgow, United Kingdom (R.N., E.M., A.N.D.C., D.S., P.M., D.G., T.J.G.).

Michal Nowak (M)

Department of Medicine, Jagiellonian University Medical College, Krakow, Poland (R.N., M.S., M.N., D.S., G.W., G.O., T.J.G.).

Aurelie Nguyen Dinh Cat (AND)

From the Institute of Cardiovascular and Medical Sciences, University of Glasgow, United Kingdom (R.N., E.M., A.N.D.C., D.S., P.M., D.G., T.J.G.).

Laura Medina-Ruiz (L)

Institute of Infection, Immunity and Inflammation, University of Glasgow, United Kingdom (L.M.-R., G.G., P.M.).

Marco Cantini (M)

Centre for the Cellular Microenvironment, School of Engineering, University of Glasgow, United Kingdom (M.C., M.S.-S.).

Dominik Skiba (D)

From the Institute of Cardiovascular and Medical Sciences, University of Glasgow, United Kingdom (R.N., E.M., A.N.D.C., D.S., P.M., D.G., T.J.G.).
Department of Medicine, Jagiellonian University Medical College, Krakow, Poland (R.N., M.S., M.N., D.S., G.W., G.O., T.J.G.).

Grzegorz Wilk (G)

Department of Medicine, Jagiellonian University Medical College, Krakow, Poland (R.N., M.S., M.N., D.S., G.W., G.O., T.J.G.).

Grzegorz Osmenda (G)

Department of Medicine, Jagiellonian University Medical College, Krakow, Poland (R.N., M.S., M.N., D.S., G.W., G.O., T.J.G.).

Julie Rodor (J)

Centre for Cardiovascular Science, Queen's Medical Research Institute, University of Edinburgh, United Kingdom (L.D., J.R., A.H.B.).

Manuel Salmeron-Sanchez (M)

Centre for the Cellular Microenvironment, School of Engineering, University of Glasgow, United Kingdom (M.C., M.S.-S.).

Gerard Graham (G)

Institute of Infection, Immunity and Inflammation, University of Glasgow, United Kingdom (L.M.-R., G.G., P.M.).

Pasquale Maffia (P)

From the Institute of Cardiovascular and Medical Sciences, University of Glasgow, United Kingdom (R.N., E.M., A.N.D.C., D.S., P.M., D.G., T.J.G.).
Institute of Infection, Immunity and Inflammation, University of Glasgow, United Kingdom (L.M.-R., G.G., P.M.).
Department of Pharmacy, University of Naples Federico II, Italy (P.M.).

Delyth Graham (D)

From the Institute of Cardiovascular and Medical Sciences, University of Glasgow, United Kingdom (R.N., E.M., A.N.D.C., D.S., P.M., D.G., T.J.G.).

Andrew H Baker (AH)

Centre for Cardiovascular Science, Queen's Medical Research Institute, University of Edinburgh, United Kingdom (L.D., J.R., A.H.B.).

Tomasz J Guzik (TJ)

From the Institute of Cardiovascular and Medical Sciences, University of Glasgow, United Kingdom (R.N., E.M., A.N.D.C., D.S., P.M., D.G., T.J.G.).
Department of Medicine, Jagiellonian University Medical College, Krakow, Poland (R.N., M.S., M.N., D.S., G.W., G.O., T.J.G.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH